This market research report provides pharmaceutical companies and contract manufacturers with a comprehensive analysis of current outsourcing trends and practices in addition to a quantitative analysis of CMO service quality across a series of 23 performance attributes specific to drug product manufacturing projects. ISR presents data on 398 service encounters from 138 respondents who have been involved in outsourced drug product projects in the past 18 months. More.
By Louis Garguilo, Chief Editor, Outsourced Pharma
Justin Klee and Joshua Cohen were just 21 and 22 when they co-founded Amylyx Pharmaceuticals in 2013, while pursuing undergraduate degrees at Brown University. Today, their insights about drug development and manufacturing outsourcing are nothing short of remarkable.
By Hector M. Samper, principal and strategic advisor, Global Strategic Sourcing Solutions (GSSS)
Measurable benefits of off-site module construction are becoming more evident, and it is emerging as a viable method for delivering a greater degree of predictability. Furthermore, market constraints driven by shortages of craft labor, lagging productivity, project complexity, and competitive forces are contributing to biopharma’s move toward modularization.
By Tobias Kuners of Koenders, managing consultant, Tob Management
The next stage in maintenance management, Maintenance 4.0, is to go beyond predictive to the initial stage of an asset — commissioning the assets and deploying the same tools and techniques to set the measures within the design specification from the beginning onward, and using indicative measures to keep the asset in its original design specification.
When CDMOs understand what motivates drug innovators to outsource, who is involved in the service provider selection decision, and which CDMO attributes have the greatest influence on CDMO selection, they are able to communicate what is unique about their offering to the right audience at the right time.